US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2019

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar intensifies ahead of ASTar launchFourth quarter, 1 October–31 December 2019 · Net sales amounted to SEK 0.0 million (0.3). · The operating result totalled SEK -62.1 million (-39.0). · The result for the period amounted to SEK -62.0 million (-39.4). · Earnings per share before and after dilution amounted to SEK -2.71 (-2.33). · Cash flow from operating activities totalled SEK -52.1 million (-37.4). Period, 1 January–31 December 2019 · Net sales amounted to SEK 1.0 million (1.

Q-linea signs global partnership with Thermo Fisher Scientific for commercialization of ASTar

Q-linea AB (publ) (OMX: QLINEA), today announced that the company has entered into a worldwide exclusive partnership with Thermo Fisher Scientific for the commercialization of ASTar.“We are very happy and proud to be able to present an important commercial milestone for both companies. The interest in commercializing ASTar® has been very strong from a number of global companies. We are thrilled to be working with Thermo Fisher and especially appreciate their global reach. We share a common market view and agree on how infection diagnosis can be improved.” said Jonas Jarvius, CEO of Q-linea.

INTERIM REPORT 1 JANUARY – 30 SEPTEMBER 2019

A quarter of intense preparation Third quarter, 1 July - 30 September 2019 · Net sales amounted to SEK 0.0 million (0.3). · The operating result totalled SEK -35.8 million (-28.8). · The result for the period amounted to SEK -35.1 million (-29.3). · Earnings per share before and after dilution amounted to SEK -1.53 (-1.98). · Cash flow from operating activities totalled SEK -35.8 million (-31.2). Period, 1 January - 30 September 2019 · Net sales amounted to SEK 1.0 million (0.8). · The operating result totalled SEK -117.1 million (-88.4). · The result for

Invitation to presentation of Q-linea’s Interim Report Q3-2019 on November 7, 2019

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim Report for the period January – September 2019 on Thursday, November 7, 2019 at 07:30 a.m. CET. Q-linea invites to an audiocast with teleconference (in English) for investors, analysts and media on November 7, at 13:00 – 14:00 p.m CET. Jonas Jarvius, CEO, and Anders Lundin, CFO, to present Q-linea and comment on the Interim Report Report for the period January – September 2019 followed by a Q&A-session. To participate, please call any of the following phone numbers from: Sweden: + 46 8 566 427 05

Q-linea receives positive response from the FDA for the design of the company's planned clinical study in the USA

Q-linea AB (publ) (OMX: QLINEA, announced today that the company has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company's planned pivotal clinical trial with ASTar® in the United States.“We are very pleased with the official feedback from the FDA which will have a very positive impact on the conduct of our clinical study in the US. We have received the clear guidance we wanted and we believe that the study can be carried out in a more straightforward way than previously estimated,

There are no items matching the current filter
There are no more items matching the current filter
Back to top